Risk of lung cancer and renin-angiotensin blockade: a concise review.

CONCLUSION: Until more comprehensive analyses have been completed, there is no need to change clinical practise. Additional prospective randomized trials with long-term follow-up are needed to investigate the effects of these drugs on the development and progression of lung cancer. PMID: 33231730 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33231730?dopt=Abstract

Source: Clin Med Res - November 24, 2020 Category: Research Authors: Rachow T, Schiffl H, Lang SM Tags: J Cancer Res Clin Oncol Source Type: research